Early stage Prostate Cancer (PC) is usually androgen-dependent and androgen ablation therapies have been used with good results in the destruction of androgen-dependent cells. However, anti-androgens are associated with systemic side effects and selection for tumour cells that survive in the absence of androgens, leading to androgen-independent PC. ELK-1 is a member of the ETS-domain transcription factor family. In response to mitogens, ERKs phosphorylate and activate ELK-1 to stimulate the expression of Immediate Early Genes (IEGs) such as CFOS and EGR1, thereby promoting cell cycle entry and proliferation. In PC cells, ELK-1 expression is frequently up-regulated and androgen receptor (AR) was found to function as a constitutive coactiv...
Elk-1 is a transcription factor that binds together with a dimer of the serum response factor (SRF)...
Purpose: Testosterone suppression in prostate cancer (PC) is limited by serious side effects and res...
PhD ThesisThe androgen receptor (AR) is a key transcription factor in prostate cancer (CaP) growth a...
Early stage Prostate Cancer (PC) is usually androgen-dependent and androgen ablation therapies have ...
The mitogen-responsive, ETS-domain transcription factor ELK-1 stimulates the expression of immediate...
Prostate cancer (PCa) growth requires tethering of the androgen receptor (AR) to chromatin by the ET...
ELK-1 is a transcription factor involved in ERK-induced cellular proliferation. Here we show that it...
The ETS domain transcription factor ELK1 is in a repressive association with growth genes and is tra...
The transcription factor ELK-1 is associated with numerous cellular processes, notably in cell proli...
Chromosomal rearrangements account for all erythroblast transformation–specific (ETS) family member ...
ELK3, an ETS domain-containing transcription factor, participates in various physiological and patho...
This study aimed to elucidate the role of ELF3, an ETS family member in normal prostate growth and p...
Prostate cancer (PCa) primarily depends on androgen receptor (AR) signaling pathway for the initiati...
The androgen receptor (AR) is the main driver of prostate cancer (PC) development and progression, a...
ETS family transcription factors play major roles in prostate tumorigenesis with some acting as onco...
Elk-1 is a transcription factor that binds together with a dimer of the serum response factor (SRF)...
Purpose: Testosterone suppression in prostate cancer (PC) is limited by serious side effects and res...
PhD ThesisThe androgen receptor (AR) is a key transcription factor in prostate cancer (CaP) growth a...
Early stage Prostate Cancer (PC) is usually androgen-dependent and androgen ablation therapies have ...
The mitogen-responsive, ETS-domain transcription factor ELK-1 stimulates the expression of immediate...
Prostate cancer (PCa) growth requires tethering of the androgen receptor (AR) to chromatin by the ET...
ELK-1 is a transcription factor involved in ERK-induced cellular proliferation. Here we show that it...
The ETS domain transcription factor ELK1 is in a repressive association with growth genes and is tra...
The transcription factor ELK-1 is associated with numerous cellular processes, notably in cell proli...
Chromosomal rearrangements account for all erythroblast transformation–specific (ETS) family member ...
ELK3, an ETS domain-containing transcription factor, participates in various physiological and patho...
This study aimed to elucidate the role of ELF3, an ETS family member in normal prostate growth and p...
Prostate cancer (PCa) primarily depends on androgen receptor (AR) signaling pathway for the initiati...
The androgen receptor (AR) is the main driver of prostate cancer (PC) development and progression, a...
ETS family transcription factors play major roles in prostate tumorigenesis with some acting as onco...
Elk-1 is a transcription factor that binds together with a dimer of the serum response factor (SRF)...
Purpose: Testosterone suppression in prostate cancer (PC) is limited by serious side effects and res...
PhD ThesisThe androgen receptor (AR) is a key transcription factor in prostate cancer (CaP) growth a...